Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Glioblastoma Multiforme Market Report Overview

The Glioblastoma Multiforme market value for the 15 markets (15M) was $630 million in 2021. This included both cell and gene therapies (CGTs) and established/traditional GBM therapies. The Glioblastoma Multiforme market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for glioblastoma multiforme (GBM).

Market Size (2021 in 15M) $630 million
Key Regions APAC, Europe, the Middle East, and North America
Leading Players ZhongSheng BioTech Inc, NantWorks LLC, IN8bio Inc, Nanjing KAEDI Biotech Inc, and Candel Therapeutics Inc

Glioblastoma Multiforme Market Drivers

One of the highest levels of unmet need across all of oncology is expected to significantly drive the uptake and usage of novel cell and gene therapy agents. Furthermore, demonstrated survival advantage and highly tolerable safety profiles for several oncolytic viruses and dendritic cell therapies provide a strong clinical rationale for usage in 1L and recurrent patients, with strong potential to displace the use of targeted therapies like bevacizumab.

For more market driver insights into the Glioblastoma Multiforme market, download a free report sample

Glioblastoma Multiforme Market Segmentation by Regions

The key regions in the Glioblastoma Multiforme market are APAC, Europe, the Middle East, and North America. North America had the highest share in 2021. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for CGT therapies given the current drug development landscape, namely Australia, Belgium, Canada, Denmark, Israel, South Korea, and Switzerland. Cell therapy, consisting mostly of autologous dendritic cell-based therapies, is the third most-abundant modality type in the GBM pipeline behind monoclonal antibodies and small molecules.

Glioblastoma Multiforme Market Analysis by Regions, 2021 (%)

Glioblastoma Multiforme Market Analysis by Regions, 2021 (%)

For more regional insights on the Glioblastoma Multiforme market, download a free report sample

Glioblastoma Multiforme Market - Competitive Landscape

Some of the leading players in the Glioblastoma Multiforme market are ZhongSheng BioTech Inc, NantWorks LLC, IN8bio Inc, Nanjing KAEDI Biotech Inc, and Candel Therapeutics Inc. Most CGT future players in GBM are US and China-based biotech companies, with a clear absence of big pharma developing CGT agents for GBM. Most future players only have one or two GBM-targeted assets in the pipeline, with 15 of the top 20 future players only having one GBM-targeted CGT asset in their pipelines.


This report provides an in-depth analysis of the following:

  • Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
  • Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecast includes 8 countries

Forecast covers 2021-2031

Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Reasons to Buy

  • Obtain cell & gene therapy sales forecasts across multiple regions
  • Gain insight into promising early-stage approaches
  • Our indication-specific forecast models answer questions such as:
  • What is the target patient pool for cell & gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in each market?
  • What is the total market value projected for the forecast end, in 2031?

Northwest Biotherapeutics
Epitopoietic Research Corporation
Istari Oncology

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. Etiology & Epidemiology

3.2. CRC Treatment Algorithm

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

5.2. 10-Year Market Outlook Across the 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

9. Future Players and Catalyst

10. Appendix

10.1. Cell & Gene Therapies Forecast Methodology Overview

10.2. Pricing of Cell & Gene Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations and Definitions

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031 standard reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031 in real time.

  • Access a live Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.